Rituximab

From Proteopedia

Revision as of 09:51, 14 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Rituximab, better known as Rituxan, (2osl)

Drag the structure with the mouse to rotate

Better Known as: Rituxan

  • Marketed By: Biogen Idec, Genentech & Roche
  • Major Indications: B-Cell & Follicular Lymphoma, Leukemia, & Rheumatoid Arthritis
  • Drug Class: Anti-CD20 Monoclonal Antibody
  • Date of FDA Approval (Patent Expiration): 1997 (2015)
  • 2009 Sales: $5.7 Billion
  • Importance: The best selling cancer treatment in the world. It was the first monoclonal antibody to be approved by the FDA which selectively targets CD20 on B-cells.
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Chronic Lymphocytic Leukemia & Rheumatoid Arthritis are diseases associated with B-cell dysfunction. B-cells play a key role in the humoral immune system by acting as antigen-presenting cells (which activate T-cells) and by eventually producing antibodies against invading antigens.[1] Although the function of B-Lymphocyte Antigen CD20 has not yet been determined, and in fact knockout mice which do not produce CD20 are healthy, CD20 is expressed on almost all normal and malignant B-cells. Since it is not expressed on other plasma cells or normal tissues, it is an ideal target for passive immunotherapy.[2][3] A number of studies have demonstrated that the binding of monoclonal antibodies to CD20 results in recruitment of immunological devices that trigger cytotoxic events, such as compliment-dependent cytotoxicity (CDC). CDC is the major natural immune response in the body triggered by antibody binding, used to eliminate invading or dysfunctional pathogenic cells.[4] Rituximab is an anti-CD20 chimeric monoclonal antibody.

References

  1. ↑ Montecino-Rodriguez E, Dorshkind K. New perspectives in B-1 B cell development and function. Trends Immunol. 2006 Sep;27(9):428-33. Epub 2006 Jul 24. PMID:16861037 doi:10.1016/j.it.2006.07.005
  2. ↑ Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, Huo S, Guo Y, Ding J. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007 May 18;282(20):15073-80. Epub 2007 Mar 29. PMID:17395584 doi:10.1074/jbc.M701654200
  3. ↑ Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-74. PMID:15564720 doi:10.1159/000082102
  4. ↑ Zhang B. Ofatumumab. MAbs. 2009 Jul-Aug;1(4):326-31. Epub 2009 Jul 1. PMID:20068404


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Joel L. Sussman, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Rituximab"
Personal tools